NCT00661427 - Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Head and NeckSquamous Cell Cancer

Interventions

BIOLOGICAL

cetuximab

Cetuximab 500 mg/m\^2 IV over 2 hours every other week

BIOLOGICAL

cetuximab

Cetuximab 750 mg/m\^2 IV over 3 hours every other week

Trial Locations (17)

10065

Memorial Sloan Kettering Cancer Center, New York

11725

Memorial Sloan-Kettering Cancer Center at Commack, Commack

19104

Abramson Cancer Center University of Pennsylvania, Philadelphia

19106

Pennsylvania Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

33612

H. Lee Moffit Cancer Center and Research Institute, Tampa

38104

University of Tennessee Cancer Institute, Memphis

60201

NorthShore University Health System, Evanston

63110

Washington University School of Medicine, St Louis

84112

Huntsman Cancer Institue, Salt Lake City

91010-3000

City of Hope National Medical Center, Duarte

68198-7680

University of Nebraska Medical Center, Omaha

07939

Memorial Sloan-Kettering Cancer Center at Basking Ridge, Basking Ridge

Unknown

Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow

08060

Fox Chase Virtua Health Cancer Program, Philadelphia

19104-4283

University of Pennsylvania - Abramson Cancer Center, Philadelphia

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Memorial Sloan Kettering Cancer Center

OTHER